Oxidation and ferroptosis markers were increased in the OVA group.
Asthma parameters, such as Th2 cytokine and IgE production, mast cell activation, goblet cell hyperplasia, hyperresponsiveness, and inflammation, were dramatically increased in the OVA group. CK, among the ginsenosides analyzed, was highly increased in FAGS compared with GS. Asthmatic parameters were analyzed in bronchoalveolar lavage fluid (BALF), blood, and lung tissue. During the challenge period, two different concentrations of FAGS and CK were administered via oral gavage. The experimental asthma model was sensitized and challenged with OVA. This study was performed to investigate the anti-asthmatic and anti-ferroptotic effects of fermented and aged ginseng sprouts (FAGS) with enhanced antioxidant activity and its main component, compound K (CK), in a mouse model of ovalbumin (OVA)-induced allergic asthma. Oxidative stress-induced ferroptosis has not been extensively studied in asthma models. The association between asthma and oxidative stress remains controversial. Adherence to the application was better than that for rhinitis, but it needs to be improved. VAS asthma appears to be an interesting patient-reported outcome highly correlated with dyspnea and impacts on work. MASK-air® can be used in patients with severe asthma.
Highly significant correlations were found for the VAS for asthma, and other patients reported VASs for work, dyspnea, sleep, and rhinitis. Five patients had over 90% well-controlled days, four had well- or moderately controlled asthma (with up to 20% uncontrolled days), one patient had moderately controlled asthma with approximately 20% uncontrolled days, and one patient had 80% uncontrolled days. Highly variably trends were found for the VAS for asthma. There was no correlation between application and medication adherence. The average application adherence was 51.8% (range: 19.7–98.9%). Thirteen patients reported on 1229 days of MASK-air® use. Adherence to MASK-air® and to the asthma treatment was also checked. The evolution of the visual analogue scales (VAS) for asthma, shortness of breath, rhinitis, conjunctivitis, work, and sleep was monitored using MASK-air®. Treatment of the patients was not changed based on the application results.
Severe asthmatics were proposed to use the MASK-air® application for 6 months, along with best practice treatment. We explored whether the MASK-air® application is applicable to patients with severe asthma. MASK-air®, a good practice of the DG Santé, has been fully validated in allergic rhinitis, but little is known about its applicability to asthmatics.
#269 M1 DECRYPTED BINDI UPDATE#
In this review, recently published articles and clinical trials are summarised and discussed with the goal to provide clinicians and researchers with a concise update on asthma research from a translational perspective. Integrating asthma management within the broader context of Planetary Health has been put forward. Several randomised clinical trials and good quality real world evidence shed new light on asthma treatment and supported the revision of several asthma guidelines (GINA, Expert Panel Report 3, ERS/ATS guidelines on severe asthma) and the conception of new ones (EAACI Guidelines for the use of biologicals in severe asthma). The precision immunology unbiased approach was supplemented with novel tools and greatly facilitated by the use of artificial intelligence. Novel key findings in asthma pathogenesis focus on the resident cell compartment, epigenetics and the innate immune system. Last year brought a significant advance in asthma management, unyielding to the pressure of the pandemics.
0 kommentar(er)
